ACHL - Achilles Therapeutics and Secarna ink research and license agreement

Achilles Therapeutics (NASDAQ:ACHL) and Secarna Pharmaceuticals have entered into a research, option and license agreement. Under the terms of the agreement, Secarna will receive an undisclosed upfront payment, a target-based technology access fee as well as option exercise fees. Secarna is also eligible to receive development and commercial milestone payments as well as tiered royalties on net sales of personalized T cell therapies developed and commercialized under this collaboration.

For further details see:

Achilles Therapeutics and Secarna ink research and license agreement